Captrust Financial Advisors Purchases 12,562 Shares of Amgen Inc. $AMGN

Captrust Financial Advisors boosted its position in shares of Amgen Inc. (NASDAQ:AMGN) by 2.6% during the 4th quarter, HoldingsChannel reports. The fund owned 498,265 shares of the medical research company’s stock after buying an additional 12,562 shares during the quarter. Captrust Financial Advisors’ holdings in Amgen were worth $163,087,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in AMGN. Norges Bank bought a new position in Amgen during the fourth quarter valued at about $2,164,162,000. Capital World Investors increased its stake in Amgen by 22.9% during the fourth quarter. Capital World Investors now owns 23,097,711 shares of the medical research company’s stock valued at $7,560,249,000 after acquiring an additional 4,302,237 shares during the period. State Street Corp increased its stake in Amgen by 4.4% during the fourth quarter. State Street Corp now owns 30,591,403 shares of the medical research company’s stock valued at $10,012,872,000 after acquiring an additional 1,287,310 shares during the period. Geode Capital Management LLC increased its stake in Amgen by 7.8% during the fourth quarter. Geode Capital Management LLC now owns 14,303,294 shares of the medical research company’s stock valued at $4,665,822,000 after acquiring an additional 1,035,779 shares during the period. Finally, Vanguard Group Inc. increased its stake in Amgen by 1.8% during the fourth quarter. Vanguard Group Inc. now owns 54,838,826 shares of the medical research company’s stock valued at $17,949,296,000 after acquiring an additional 961,975 shares during the period. 76.50% of the stock is currently owned by institutional investors.

Insider Transactions at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of the company’s stock in a transaction on Monday, May 4th. The stock was sold at an average price of $323.73, for a total transaction of $400,454.01. Following the transaction, the senior vice president owned 7,009 shares of the company’s stock, valued at approximately $2,269,023.57. This represents a 15.00% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.85% of the company’s stock.

Amgen Stock Down 0.8%

Shares of AMGN opened at $347.84 on Wednesday. The company has a market capitalization of $187.73 billion, a P/E ratio of 24.21, a PEG ratio of 3.52 and a beta of 0.42. The company has a debt-to-equity ratio of 5.65, a current ratio of 1.26 and a quick ratio of 1.01. Amgen Inc. has a one year low of $267.83 and a one year high of $391.29. The business’s 50 day simple moving average is $341.02 and its 200-day simple moving average is $345.89.

Amgen (NASDAQ:AMGN) last announced its earnings results on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, topping the consensus estimate of $4.77 by $0.38. The business had revenue of $8.62 billion for the quarter, compared to the consensus estimate of $8.58 billion. Amgen had a return on equity of 137.41% and a net margin of 20.96%.Amgen’s revenue was up 5.8% compared to the same quarter last year. During the same period in the previous year, the business earned $4.90 EPS. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. As a group, sell-side analysts predict that Amgen Inc. will post 22.38 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

AMGN has been the topic of several research reports. Canaccord Genuity Group initiated coverage on Amgen in a research note on Monday, April 20th. They set a “hold” rating and a $366.00 price target on the stock. Leerink Partners reiterated a “market perform” rating and issued a $355.00 price objective on shares of Amgen in a research note on Thursday, March 5th. Jefferies Financial Group began coverage on Amgen in a research note on Tuesday, March 10th. They issued a “hold” rating and a $350.00 price objective on the stock. Morgan Stanley upped their price objective on Amgen from $332.00 to $340.00 and gave the company an “equal weight” rating in a research note on Tuesday, June 9th. Finally, Freedom Capital upgraded Amgen from a “hold” rating to a “strong-buy” rating in a research note on Thursday, May 7th. Two analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, fifteen have given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, Amgen presently has a consensus rating of “Hold” and a consensus price target of $354.42.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.